Update shared on08 Aug 2025
Fair value Increased 6.31%Upward revisions to Niagen Bioscience's price target reflect positive clinical trial results confirming both safety and significant efficacy of its NAD+ supplementation, increased market confidence, and ongoing product and sales momentum, resulting in a higher consensus analyst price target rising from $14.90 to $15.84.
Analyst Commentary
- Positive clinical study results published in a peer-reviewed journal demonstrated that Niagen Bioscience’s NAD+ supplementation is safe for patients with Werner syndrome and achieved a ~140% increase in blood NAD+ levels, along with improvements in liver, kidney, and arterial health markers.
- Bullish analysts view the successful completion of a double-blind, placebo-controlled trial as a significant milestone, providing strong validation of the company’s core science and product efficacy.
- The company’s stock has exhibited strong performance over the past year, reflecting increasing investor confidence and robust market sentiment.
- Significant upside potential remains due to expanding addressable markets, driven by multiple clinical trials and studies in progress with the possibility for broader indications.
- Continued strong sales growth of TruNiagen, resilience against tariff impacts, and successful rollout of new products and initiatives, such as Niagen Plus in clinics, further support higher price targets.
What's in the News
- Niagen Bioscience raised full-year 2025 revenue growth guidance to 22%-27% year-over-year.
- Tru Niagen introduced as an in-room amenity and Niagen IV now offered at Equinox Hotel New York, expanding presence in the luxury hospitality sector.
- Secured exclusive worldwide license with Haukeland University Hospital for proprietary data supporting regulatory approval of a nicotinamide riboside therapy for Parkinson’s Disease; formed a new subsidiary to drive drug development.
- Published positive clinical data showing Niagen supplementation significantly elevated NAD+ levels and improved health markers in patients with Werner syndrome, supporting efficacy for rare, age-related diseases.
Valuation Changes
Summary of Valuation Changes for Niagen Bioscience
- The Consensus Analyst Price Target has risen from $14.90 to $15.84.
- The Net Profit Margin for Niagen Bioscience has significantly risen from 14.70% to 16.45%.
- The Future P/E for Niagen Bioscience has fallen from 59.36x to 55.89x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.